![Brief Your CEO: New SCOTUS Case May Help Your Lab Defend Meritless Whistleblower Cases](https://www.g2intelligence.com/wp-content/uploads/2023/07/Aug23.LCA_.BriefCEO.SCOTUSQuiTamCase-iStock-1100x800-1-1080x675.jpg)
Brief Your CEO: New SCOTUS Case May Help Your Lab Defend Meritless Whistleblower Cases
A recent SCOTUS ruling on a healthcare fraud case could help defend labs against baseless whistleblower cases.
A recent SCOTUS ruling on a healthcare fraud case could help defend labs against baseless whistleblower cases.
Last month’s key cases involved the outcome of a UHC lawsuit and fines for misleading claims about a COVID-19 test.
Ruling could spell good news for labs and other healthcare providers targeted by whistleblowers in False Claims Act qui tam lawsuits.
False billing of urine drug tests (UDTs) continues to be a focus for enforcement agencies in 2023, here’s how to avoid compliance issues.
Recent cases involve COVID-19 fraud, UDTs, and the latest HIPAA Right of Access settlement.